Annual report pursuant to Section 13 and 15(d)

Schedule of Deferred Tax Assets and Related Valuation Allowances (Details)

v3.24.1
Schedule of Deferred Tax Assets and Related Valuation Allowances (Details) - USD ($)
Dec. 31, 2023
Dec. 31, 2022
Income Tax Disclosure [Abstract]    
Reserves and other $ 796,000 $ 745,000
Net operating loss carry-forwards 26,494,000 26,176,000
Capitalized research and development 3,946,000 2,177,000
Research and development tax credit 1,326,000 610,000
Share-based compensation 1,108,000 4,542,000
Warrant liability (2,860,000)
Derivative liability (688,000)
Valuation Allowance (30,122,000) (34,250,000)
Net deferred tax asset